-+ 0.00%
-+ 0.00%
-+ 0.00%

Marker Therapeutics Receives $2.6 Million FDA Grant for Pancreatic Cancer Study

PUBT·10/19/2026 11:10:35
Listen to the news
Marker Therapeutics Receives $2.6 Million FDA Grant for Pancreatic Cancer Study
  • Marker Therapeutics received a $2.6 million FDA grant for a Phase 1 trial of MT-601 in locally advanced unresectable pancreatic cancer.
  • The trial is expected to begin in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190700PRIMZONEFULLFEED9848001) on October 19, 2026, and is solely responsible for the information contained therein.